Browsing Tag
PRMT5
2 posts
Tango Therapeutics (TNGX) soars on striking pancreatic cancer data, then moves to cash in
Tango Therapeutics soared 50%+ on early pancreatic cancer data, a 92% response rate for vopimetostat plus daraxonrasib, then filed a $500M offering to cash in.
Tango Therapeutics (NASDAQ: TNGX) jumps 11% into May 11 earnings and pivotal pancreatic cancer data
Tango Therapeutics is up 22-fold from $1.04 in twelve months. The May 11 earnings print decides whether vopimetostat justifies the run or breaks it.